US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
US5374548A
(en)
|
1986-05-02 |
1994-12-20 |
Genentech, Inc. |
Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
|
MX9203291A
(es)
|
1985-06-26 |
1992-08-01 |
Liposome Co Inc |
Metodo para acoplamiento de liposomas.
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4881175A
(en)
|
1986-09-02 |
1989-11-14 |
Genex Corporation |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
US5013653A
(en)
|
1987-03-20 |
1991-05-07 |
Creative Biomolecules, Inc. |
Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
EP0623679B1
(en)
|
1987-05-21 |
2003-06-25 |
Micromet AG |
Targeted multifunctional proteins
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
US5804381A
(en)
|
1996-10-03 |
1998-09-08 |
Cornell Research Foundation |
Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
US5476996A
(en)
|
1988-06-14 |
1995-12-19 |
Lidak Pharmaceuticals |
Human immune system in non-human animal
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
CA2006596C
(en)
|
1988-12-22 |
2000-09-05 |
Rika Ishikawa |
Chemically-modified g-csf
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
SG48759A1
(en)
|
1990-01-12 |
2002-07-23 |
Abgenix Inc |
Generation of xenogenic antibodies
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US6235525B1
(en)
|
1991-05-23 |
2001-05-22 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
|
PT1696031E
(pt)
|
1991-12-02 |
2010-06-25 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
EP0746609A4
(en)
|
1991-12-17 |
1997-12-17 |
Genpharm Int |
NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5620886A
(en)
|
1993-03-18 |
1997-04-15 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
|
EP0754225A4
(en)
|
1993-04-26 |
2001-01-31 |
Genpharm Int |
HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
CA2156924A1
(en)
|
1993-12-27 |
1995-07-06 |
Ton That Hai |
Water soluble non-immunogenic polyamide cross-linking agents
|
US5759546A
(en)
|
1994-02-04 |
1998-06-02 |
Weinberg; Andrew D. |
Treatment of CD4 T-cell mediated conditions
|
US6242566B1
(en)
|
1994-02-10 |
2001-06-05 |
Board Of Trustees Of The Leland Stanford Junior University |
Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US6548530B1
(en)
|
1995-10-03 |
2003-04-15 |
The Scripps Research Institute |
CBI analogs of CC-1065 and the duocarmycins
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
US6069233A
(en)
|
1996-10-03 |
2000-05-30 |
Memorial Sloan-Kettering Cancer Center |
Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド |
免疫療法のctla−4結合ペプチド
|
EP1724282B1
(en)
|
1997-05-21 |
2013-05-15 |
Merck Patent GmbH |
Method for the production of non-immunogenic proteins
|
CA2321161C
(en)
|
1998-02-24 |
2011-12-20 |
Andrew D. Weinberg |
Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
|
US6312700B1
(en)
*
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ATE375365T1
(de)
|
1998-04-02 |
2007-10-15 |
Genentech Inc |
Antikörper varianten und fragmente davon
|
DK2180007T4
(da)
|
1998-04-20 |
2017-11-27 |
Roche Glycart Ag |
Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
RS51309B
(sr)
|
1998-12-23 |
2010-12-31 |
Pfizer Inc. |
Humana monoklonalna antitela za ctla-4
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
JP4118462B2
(ja)
|
1999-07-19 |
2008-07-16 |
株式会社リコー |
携帯電子機器
|
EP1074563A1
(en)
|
1999-08-02 |
2001-02-07 |
F. Hoffmann-La Roche Ag |
Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
|
DE60033293D1
(de)
|
1999-08-23 |
2007-03-22 |
Dana Farber Cancer Inst Inc |
Neue b7-4 moleküle und deren verwendungen
|
CN1371416B
(zh)
|
1999-08-24 |
2012-10-10 |
梅达里克斯公司 |
人ctla-4抗体及其应用
|
NZ529329A
(en)
|
1999-08-25 |
2005-06-24 |
Immunex Corp |
Compositions and methods for improved cell culture
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
US6774226B1
(en)
|
1999-11-30 |
2004-08-10 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
|
ATE336514T1
(de)
|
2000-02-11 |
2006-09-15 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
IL151865A0
(en)
|
2000-03-31 |
2003-04-10 |
Genentech Inc |
Compositions and methods for detecting and quantifying gene expression
|
KR100857943B1
(ko)
|
2000-11-30 |
2008-09-09 |
메다렉스, 인코포레이티드 |
인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
US6794501B2
(en)
|
2001-05-04 |
2004-09-21 |
Ludwig Institute For Cancer Research |
Colon cancer antigen panel
|
JP2004532038A
(ja)
|
2001-05-17 |
2004-10-21 |
ディヴァーサ コーポレイション |
新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
|
ITMI20011465A1
(it)
|
2001-07-10 |
2003-01-10 |
Novuspharma Spa |
Gene ad attivita' oncosoppressiva
|
KR100988949B1
(ko)
|
2001-10-25 |
2010-10-20 |
제넨테크, 인크. |
당단백질 조성물
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
US20040014194A1
(en)
|
2002-03-27 |
2004-01-22 |
Schering Corporation |
Beta-secretase crystals and methods for preparing and using the same
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
EP1525223B1
(en)
|
2002-06-13 |
2007-11-21 |
Crucell Holland B.V. |
Ox40 (=cd134) receptor agonists and therapeutic use
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
CN101987871A
(zh)
|
2002-09-27 |
2011-03-23 |
赞科股份有限公司 |
优化的Fc变体及其产生方法
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
EP2364716A3
(en)
|
2002-11-08 |
2012-01-11 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
US20040197312A1
(en)
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
CN102940889A
(zh)
|
2003-05-14 |
2013-02-27 |
伊缪诺金公司 |
药物缀合物组合物
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
ATE535249T1
(de)
|
2003-06-13 |
2011-12-15 |
Univ Pennsylvania |
Vakzine, immuntherapeutika und verfahren zu ihrer verwendung
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
WO2005047459A2
(en)
*
|
2003-08-04 |
2005-05-26 |
University Of Massachusetts |
Sars nucleic acids, proteins, antibodies, and uses thereof
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
KR101438983B1
(ko)
|
2003-11-06 |
2014-09-05 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
DK1706424T3
(da)
|
2004-01-12 |
2009-11-02 |
Applied Molecular Evolution |
FC-region varianter
|
US20050288491A1
(en)
|
2004-02-17 |
2005-12-29 |
Wilson David S |
Super-humanized antibodies against respiratory syncytial virus
|
CA2561264A1
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
US7778814B2
(en)
|
2004-03-30 |
2010-08-17 |
Siemens Aktiengesellschaft |
Method and device for simulating an automation system
|
US7740847B2
(en)
|
2004-08-04 |
2010-06-22 |
Applied Molecular Evolution, Inc. |
Variant Fc regions
|
CN101076542A
(zh)
*
|
2004-09-13 |
2007-11-21 |
伊沃詹尼克斯有限公司 |
特异性针对肝细胞癌和其他癌的抗体及其用途
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
DE112005002883T5
(de)
|
2004-11-23 |
2008-01-17 |
PIP Co., Ltd., Bucheon |
Wasseranschlussbox für Wandeinbau
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
EP2535355B1
(en)
*
|
2005-03-23 |
2019-01-02 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
ES2427646T5
(es)
|
2005-05-09 |
2017-08-22 |
Ono Pharmaceutical Co., Ltd. |
Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
|
CN101212967A
(zh)
|
2005-05-10 |
2008-07-02 |
因塞特公司 |
吲哚胺2,3-双加氧酶调节剂及其用法
|
ES2523666T3
(es)
|
2005-05-31 |
2014-11-28 |
Board Of Regents, The University Of Texas System |
Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
|
MX2007015942A
(es)
|
2005-07-01 |
2008-03-07 |
Medarex Inc |
Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
|
WO2007038868A2
(en)
|
2005-10-03 |
2007-04-12 |
The University Of British Columbia |
Novel enediyne compound and uses thereof
|
US20080206246A1
(en)
|
2006-04-05 |
2008-08-28 |
Ravetch Jeffrey V |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
RS52804B
(en)
*
|
2005-12-08 |
2013-10-31 |
Medarex Inc. |
HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND THEIR USE
|
CA2634198C
(en)
|
2005-12-20 |
2014-06-03 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
WO2007084559A2
(en)
|
2006-01-13 |
2007-07-26 |
Board Of Regents, The University Of Texas System |
Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
|
PE20080102A1
(es)
|
2006-05-25 |
2008-02-11 |
Bristol Myers Squibb Co |
Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
|
PE20080316A1
(es)
|
2006-05-25 |
2008-04-10 |
Bristol Myers Squibb Co |
Compuestos de aziridinil-epotilona
|
WO2007149880A2
(en)
|
2006-06-21 |
2007-12-27 |
Genentech, Inc. |
Crystal structure of ox40l and ox40l complexed with ox40 receptor
|
CA2663057C
(en)
|
2006-09-19 |
2015-12-08 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
US20100136030A1
(en)
|
2007-02-27 |
2010-06-03 |
Lamhamedi-Cherradi Salah-Eddine |
Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
BRPI0810710A2
(pt)
|
2007-05-02 |
2014-10-21 |
Hoffmann La Roche |
Método para estabilização de uma proteína.
|
KR101380732B1
(ko)
|
2007-05-30 |
2014-04-10 |
포항공과대학교 산학협력단 |
면역글로불린 융합 단백질
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
DE102007036200A1
(de)
|
2007-08-02 |
2009-02-05 |
Knorr-Bremse Systeme für Nutzfahrzeuge GmbH |
Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
|
CA2697032C
(en)
|
2007-08-22 |
2021-09-14 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
US20090181037A1
(en)
|
2007-11-02 |
2009-07-16 |
George Heavner |
Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
|
JP5583592B2
(ja)
|
2007-11-30 |
2014-09-03 |
ニューリンク ジェネティクス コーポレイション |
Ido阻害剤
|
US8815237B2
(en)
|
2007-12-05 |
2014-08-26 |
Massachusetts Institute Of Technology |
Aglycosylated immunoglobulin mutants
|
MX2010006466A
(es)
*
|
2007-12-14 |
2010-09-28 |
Bristol Myers Squibb Co |
Moleculas de union al receptor ox40 de humano.
|
EP3825329A1
(en)
|
2007-12-26 |
2021-05-26 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
US20090258013A1
(en)
|
2008-04-09 |
2009-10-15 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
JP2011516603A
(ja)
|
2008-04-17 |
2011-05-26 |
アブリンクス エン.ヴェー. |
血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
|
CA2975228C
(en)
|
2008-05-02 |
2020-07-21 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
JP2012511033A
(ja)
|
2008-12-08 |
2012-05-17 |
テゴファーム コーポレーション |
多価化合物の可逆阻害用マスキングリガンド
|
HUE034832T2
(hu)
|
2008-12-09 |
2021-12-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
|
WO2010091122A1
(en)
|
2009-02-03 |
2010-08-12 |
Amunix, Inc. |
Extended recombinant polypeptides and compositions comprising same
|
AU2010216152B2
(en)
|
2009-02-17 |
2015-05-14 |
Ucb Biopharma Sprl |
Antibody molecules having specificity for human OX40
|
US20110007023A1
(en)
|
2009-07-09 |
2011-01-13 |
Sony Ericsson Mobile Communications Ab |
Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
|
US8394922B2
(en)
|
2009-08-03 |
2013-03-12 |
Medarex, Inc. |
Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
|
WO2011056652A1
(en)
|
2009-10-28 |
2011-05-12 |
Newlink Genetics |
Imidazole derivatives as ido inhibitors
|
ES2646863T3
(es)
|
2009-11-24 |
2017-12-18 |
Medimmune Limited |
Agentes de unión específica contra B7-H1
|
MX346912B
(es)
|
2009-12-07 |
2017-04-05 |
Univ Leland Stanford Junior |
Metodos para mejorar terapia con anticuerpos antitumor.
|
CN104131035A
(zh)
|
2009-12-10 |
2014-11-05 |
瑞泽恩制药公司 |
生产重链抗体的小鼠
|
BR112012013717B1
(pt)
|
2009-12-10 |
2020-01-28 |
Hoffmann La Roche |
anticorpos de ligação ao csf-1r humano, composição farmacêutica e usos do anticorpo
|
GB201001791D0
(en)
|
2010-02-03 |
2010-03-24 |
Ucb Pharma Sa |
Process for obtaining antibodies
|
HUE026229T2
(en)
|
2010-02-08 |
2016-06-28 |
Regeneron Pharma |
Common light chain mouse
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
JP5705242B2
(ja)
|
2010-02-19 |
2015-04-22 |
ゼンコア インコーポレイテッド |
新規ctla4−ig免疫アドヘシン
|
HUE045487T2
(hu)
|
2010-03-04 |
2019-12-30 |
Macrogenics Inc |
B7-H3-ra reaktív antitestek, immunológiailag aktív fragmenseik és alkalmazásaik
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 csf-1r에 대한 항체 및 이의 용도
|
KR101647871B1
(ko)
|
2010-03-05 |
2016-08-11 |
에프. 호프만-라 로슈 아게 |
인간 csf-1r에 대한 항체 및 이의 용도
|
NZ602933A
(en)
|
2010-04-15 |
2014-09-26 |
Seattle Genetics Inc |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
BR112012026801B8
(pt)
|
2010-04-15 |
2021-05-25 |
Medimmune Ltd |
conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
|
ES2706412T3
(es)
|
2010-05-04 |
2019-03-28 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen a CSF1R
|
NZ627119A
(en)
|
2010-06-22 |
2015-05-29 |
Regeneron Pharma |
Hybrid light chain mice
|
EP2399604A1
(en)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
MY171312A
(en)
|
2010-08-23 |
2019-10-08 |
Univ Texas |
Anti-ox40 antibodies and methods of using the same
|
PL2614082T3
(pl)
|
2010-09-09 |
2019-02-28 |
Pfizer Inc. |
Cząsteczki wiążące 4-1BB
|
EP2656073A4
(en)
|
2010-12-20 |
2014-12-17 |
Univ Rockefeller |
MODULATION AGONISTIC TNFR ANTIBODY
|
US20140093496A1
(en)
|
2011-02-25 |
2014-04-03 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
|
ES2608835T3
(es)
|
2011-04-13 |
2017-04-17 |
Bristol-Myers Squibb Company |
Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
|
NO2694640T3
(ja)
|
2011-04-15 |
2018-03-17 |
|
|
MX338353B
(es)
|
2011-04-20 |
2016-04-13 |
Medimmune Llc |
Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
JP5708369B2
(ja)
|
2011-08-24 |
2015-04-30 |
コベルコ建機株式会社 |
作業機械
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
CA2849039C
(en)
|
2011-09-20 |
2018-09-18 |
Spirogen Sarl |
Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
|
WO2013095738A2
(en)
|
2011-09-27 |
2013-06-27 |
Mapp Biopharmaceutical, Inc. |
Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins
|
JP6138813B2
(ja)
|
2011-11-28 |
2017-05-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
抗pd−l1抗体及びその使用
|
WO2013087699A1
(en)
|
2011-12-15 |
2013-06-20 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
IN2014CN04765A
(ja)
|
2011-12-19 |
2015-09-18 |
Univ Rockefeller |
|
CA2863818A1
(en)
|
2012-02-06 |
2013-08-15 |
Brendan CURTI |
Cancer treatment and monitoring methods using ox40 agonists
|
CA2861122A1
(en)
|
2012-02-06 |
2013-08-15 |
Genentech, Inc. |
Compositions and methods for using csf1r inhibitors
|
TW201336851A
(zh)
|
2012-02-13 |
2013-09-16 |
必治妥美雅史谷比公司 |
烯二炔化合物,其共軛物及彼等之用途與方法
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
BR112014028013A2
(pt)
|
2012-05-11 |
2018-02-27 |
Five Prime Therapeutics Inc |
métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea
|
EP2850102A1
(en)
|
2012-05-15 |
2015-03-25 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
CA2882804A1
(en)
|
2012-08-31 |
2014-03-06 |
Brian Wong |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
MY172863A
(en)
|
2012-09-13 |
2019-12-13 |
Bristol Myers Squibb Co |
Fibronectin based scaffold domain proteins that bind to myostatin
|
EP2925350B1
(en)
|
2012-12-03 |
2019-01-30 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
WO2014116846A2
(en)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
MX356698B
(es)
|
2013-02-14 |
2018-06-11 |
Bristol Myers Squibb Co |
Compuestos de tubulisina, metodos para obtenerlos y uso.
|
MD20180107A2
(ro)
*
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
RS60826B1
(sr)
|
2013-07-16 |
2020-10-30 |
Hoffmann La Roche |
Postupci lečenja kancera upotrebom antagonista vezivanja pd-1 ose i tigit inhibitora
|
CA2933881A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
KR20160099092A
(ko)
|
2013-12-17 |
2016-08-19 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
WO2015131176A1
(en)
|
2014-02-28 |
2015-09-03 |
Podack Eckhard R |
Compositions, methods, and kits for treatment of cancer
|
PT3126394T
(pt)
|
2014-03-31 |
2019-12-19 |
Hoffmann La Roche |
Anticorpos anti-ox40 e métodos de utilização
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
ES2910446T3
(es)
|
2014-07-09 |
2022-05-12 |
Birdie Biopharmaceuticals Inc |
Combinaciones anti-PD-L1 para tratar tumores
|
CN112546231A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗-ox40抗體及其用途
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
CA3003133C
(en)
|
2014-10-24 |
2020-09-15 |
StemImmune, Incorporated |
Combination immunotherapy approach for treatment of cancer
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
JP7305300B2
(ja)
|
2014-11-05 |
2023-07-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
併用免疫療法
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
CA2987410A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|